Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cuts chemotherapy side effect by over 60% in breast cancer patients

NCT ID NCT07671547

Disease control Sponsor: MIPO Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only 14% of those taking Naderin developed low white blood cell counts, compared to 39% in the control group, suggesting Naderin may help reduce this common side effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Naderin (sodium deoxyribonucleate)
What this could lead to
If it works, this could help breast cancer patients avoid low white blood cell counts during chemotherapy and complete their treatment with fewer interruptions.
What could go wrong
This is a small, completed Phase 2/3 trial with only 79 participants. The results may not apply to all breast cancer patients or other chemotherapy regimens. Naderin is not widely available or approved for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

79 people

The number who actually took part.

Started

Jan 2014

Finished

Dec 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed histological diagnosis of breast cancer * Receiving first-line AC chemotherapy (doxorubicin + cyclophosphamide) * Age 18 years or older * Female sex * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate bone marrow function (absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L) * Adequate hepatic function (transaminases ≤ 2.5 × upper limit of normal) * Adequate renal function (creatinine ≤ 1.5 × upper limit of normal) * Normal cardiac function (left ventricular ejection fraction ≥ 50%) * Willing and able to provide written informed consent Exclusion Criteria: * Previous chemotherapy or radiotherapy for breast cancer * History of other malignant neoplasms (except non-melanoma skin cancer or carcinoma in situ of the cervix) * Severe organ dysfunction (cardiac, hepatic, renal, pulmonary) * Active infection requiring systemic therapy * Known hypersensitivity to Naderin or any of its components * Known hypersensitivity to doxorubicin, cyclophosphamide, or any excipients * Pregnancy or breastfeeding * Psychiatric or cognitive impairment that would interfere with study participation * Participation in another interventional clinical trial within 30 days prior to enrollment * Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hematologic disorder leukopenia prevention target neutropenia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy-induced myelosuppression Hematologic disorder Leukopenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.